natgillin/translations-raw huggingface dataset:
Bravecto tablets are given around the dog’s feeding time as a tablet of the appropriate strength for the dog’s bodyweight.
Zdravilo Bravecto v obliki tablet se daje približno v času hranjenja, pri čemer se uporabi ena tableta, katere jakost ustreza telesni masi psa.
BRAVO
študija BRAVO
Bray Business Park, Kilruddery, County Wicklow.
Bray Business Park, Kilruddery, County Wicklow Irska
Brazil (Belém) 2008-2009
Brazilija (Belém) 2008-2009
Brazil (Recife) 2006-2008
Brazilija (Recife) 2006-2008
Bre ast-feeding
Doje nje
break of sac of fluid within the ovaries (ovarian cyst ruptured) breast swelling.
predrtje votlinice s tekočino v jajčnikih (ciste na jajčnikih), otekanje dojk.
Break off the cap
Odlomite pokrovček.
Break off the tamper-proof plastic tip from the solvent syringe by snapping the perforation of the cap.
Zaščitno plastično konico z brizge z vehiklom odlomite tako, da prelomite po perforaciji zaporke.
Break off the tamper-resistant plastic tip cap from the solvent syringe by snapping the perforation of the cap.
Odlomite varnostni plastični pokrovček z brizge z vehiklom, tako da ga prelomite po perforaciji.
Break off the top of the ampoule of solvent.
Odlomite vrh ampule z vehiklom.
Break off the white, tamper-resistant, plastic cap from the solvent syringe by bending at the perforation cap until it snaps off.
Odlomite bel plastični varnostni pokrovček s konice injekcijske brizge z vehiklom tako, da ga pregibate na perforaciji pokrovčka, dokler se ne prelomi.
BREAK SEAL
dulaglutid
BREAK SEAL
PRETRGAJTE ZAŠČITNO OZNAKO
Break the labelled seal and remove the cap (see picture 1).
Prelomite označeno tesnilo in odstranite pokrovček (glejte sliko 1).
Break the seal of the needle, using a twisting motion, and remove the needle cap as pictured.
Z zasukom pretrgajte zaš itno oznako in odstranite pokrov ek, kot je prikazano na sliki.
BREAK-MB was a multicentre, open-label, two-cohort, Phase II study designed to evaluate the intracranial response of dabrafenib in subjects with histologically confirmed (Stage IV) BRAF- mutation positive (V600E or V600K) melanoma metastatic to the brain.
Študija BREAK-MB je bila multicentrična, odprta, dvokohortna študija II. faze za oceno intrakranialnega odziva na dabrafenib pri bolnikih s histološko potrjenim (stadij IV) melanomom z mutacijo BRAF (V600E ali V600K) in metastazami na možganih.
Break-through bleeding and spotting may occur during treatment.
Med zdravljenjem se lahko pojavijo vmesne krvavitve in krvavkast izcedek.
breakdown of muscle fibers and pain in muscles (rhabdomyolysis), abnormal posture
razgradnja mišičnih vlaken in bolečina v mišicah (rabdomioliza), nenormalna telesna drža
breakdown of muscle fibers and pain in muscles (rhabdomyolysis), abnormal posture an increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes released with muscle breakdown, joint swelling, muscle weakness
razgradnja mišičnih vlaken in bolečina v mišicah (rabdomioliza), nenormalna telesna drža zvišana koncentracija CPK (kreatin fosfokinaze) v krvi; encima, ki se včasih sprosti ob razpadanju mišic, mišičnih krčih, okorelosti sklepov, otekanju sklepov, šibkosti mišic
Breakdown of muscle fibers leading to other complications
razkroj mišičnih vlaken, ki vodi do drugih zapletov
breakdown of muscle fibers resulting in the release of muscle fiber contents (myoglobin) into the bloodstream;
razpad mišičnih vlaken, ki privede do sproščanja vsebine mišičnih vlaken (mioglobina) v krvni obtok;
breakdown of muscle fibres and pain in muscles (rhabdomyolysis), abnormal posture newborn babies born to mothers who have taken TREVICTA during pregnancy may experience side effects of the drug and/or withdrawal symptoms, such as irritability, slow, or sustained muscle contractions, shaking, sleepiness, breathing, or feeding problems a decrease in body temperature, dead skin cells at injection site, an ulcer at injection site.
razgradnja mišičnih vlaken in bolečine v mišicah (rabdomioliza), nenormalna telesna drža pri novorojenčkih mater, ki so v nosečnosti prejemale zdravilo TREVICTA, se lahko pojavijo neželeni učinki zdravila in/ali odtegnitveni simptomi, kot so razdražljivost, počasni ali dolgotrajni krči mišic, tresenje, zaspanost, nemir, težave z dihanjem in motnje hranjenja znižanje telesne temperature, odmrle kožne celice na mestu injiciranja, razjede na mestu injiciranja.
breakdown of muscle fibres resulting in the release of muscle fibre contents (myoglobin) into the bloodstream;
razpad mišičnih vlaken, ki privede do sproščanja vsebine mišičnih vlaken (mioglobina) v krvni obtok;
breakdown of muscle tissue
razgradnja mišičnega tkiva
breakdown of muscle tissue
razgradnja mišičnega tkiva,
breakdown of muscle tissue a worsening of liver disease after Lamivudine Teva is stopped or during treatment if the hepatitis B virus becomes resistant to Lamivudine Teva.
oslabelost mišičnega tkiva; poslabšanje jetrnih bolezni v primeru prekinitve jemanja zdravila Lamivudin Teva ali med zdravljenjem, postane virus hepatitisa B odporen proti zdravilu Lamivudin Teva.
breakdown of muscle tissue a worsening of liver disease after Zeffix is stopped or during treatment if the hepatitis B virus becomes resistant to Zeffix.
oslabelost mišičnega tkiva; poslabšanje jetrnih bolezni v primeru prekinitve jemanja zdravila Zeffix ali med zdravljenjem, če postane virus hepatitisa B odporen proti zdravilu Zeffix.
breakdown of muscle tissue liver disorders, such as jaundice, enlarged liver or fatty liver, inflammation (hepatitis).
razpad mišičnega tkiva, težave z jetri, kot so zlatenica, povečana ali zamaščena jetra, vnetje jeter (hepatitis).
breakdown of muscle, muscle pain or weakness
razgradnja mišic, bolečina v mišicah ali šibkost;
breakdown of muscle, muscle pain or weakness
razpad mišičnega tkiva, bolečine v mišicah ali mišična oslabelost
breakdown of red blood cells (haemolytic anaemia)
razpadanje rdečih krvnih celic (hemolitična anemija)
breaking of finger nails and toe nails
lomljivost nohtov na rokah in nogah
breaking of finger nails and toe nails;
lomljivost nohtov na rokah in nogah;
Breakpoints
Mejne vrednosti
Breakpoints
Mejni vrednosti
Breakpoints
Prekinitvene točke
Breakpoints
Referenčne vrednosti
Breakpoints EUCAST breakpoints
Mejne vrednosti
Breakthrough Aspergillus infections were observed in 1 versus 7 patients, and proven or probable breakthrough Candida infections were observed in 4 versus 2 patients in the micafungin and fluconazole groups, respectively.
V skupini, ki je prejemala mikafungin in v skupini, ki je prejemala flukonazol so izbruhe okužb z Aspergillus opazili pri 1 v primerjavi z 7 bolniki in dokazanega ali verjetnega izbruha okužbe s Candida pri 4 v primerjavi z 2 bolnikoma.
Breakthrough IFI – Day 180
Izbruh IGO – 180. dan
Breakthrough pain comes on suddenly.
Prebijajoča bolečina se pojavi nenadoma.
Breakthrough varicella and zoster cases were usually mild.
Izbruhi noric in pasavca so bili običajno blagi.
Breast
povečanje dojk,
Breast
Rak dojke
breast (injection site)
dojka (mesto injiciranja)
Breast cancer
Karcinom dojk
Breast cancer
Rak dojk:
Breast cancer All severities n=254 ( 5%)
Rak dojk Vse jakosti n=254 ( 5%)
Breast cancer Grades 3/4 n=254 ( 5%)
Rak dojk stadij 3. ali 4. stopnje n=254 ( 5%)
Breast cancer n=404 (1-5%) not previously reported in clinical trials
Rak dojk n=404 (1-5%) ki še niso bili poročano v kliničnih preskušanjih
Breast cancer patients
Bolnice z rakom dojk
Breast cancer program
Raziskava pri bolnicah z rakom dojk
Breast cancer resistance protein (BCRP)
Protein odpornosti pri raku dojke (BCRP, breast cancer resistance protein)
Breast cancer resistance protein (BCRP) and P-glycoprotein substrates
Protein odpornosti za raka dojke (BCRP – Breast Cancer Resistance Protein) in substrati glikoproteina P
breast cancer that is advanced (has started to spread) in women who have been through their menopause.
napredovalega raka dojke (ki se je začel širiti) pri ženskah po menopavzi.
Breast cancer which has spread to other parts of the body (this is called “metastatic” breast cancer).
Rak dojk, ki se je razširil v druge dele telesa (to se imenuje »metastatski« rak dojk).
Breast cancer, melanoma, and squamous cell carcinoma of the oral cavity applications in adults:
Uporaba pri raku dojke, melanomu in skvamoznem karcinomu ustne votline pri odraslih:
breast cancer.
Rak dojke
breast cancer.
raka dojke.
breast cancer.
raku dojke.
Breast cancer/Ovarian cancer
Rak dojk in rak jajčnikov
Breast cancer/Ovarian cancer/Multiple myeloma
Rak dojke/rak jajčnikov/diseminirani plazmocitom
Breast cancer:
Rak dojk
Breast complaints (including tenderness)
težave z dojkami (vključno z bolečnostjo)
Breast complaints include tenderness, pain and/or engorgement and nipple pain
Med težave z dojkami sodijo občutljivost, bolečine in/ali nabreklost dojk ter boleče bradavice.
breast cyst
cista na dojki
Breast cyst, clitoral engorgement, enlarged clitoris, genital pruritus, vaginal burning sensation
cista na dojki, nabrekanje klitorisa, povečanje klitorisa, genitalni pruritus, občutek pečenja v vagini
Breast development
razvoj dojk
Breast discharge, abnormal breast growth, breast growth in males
izcedek iz dojk, nenormalna rast dojk, rast tkiva dojk pri moških
Breast discharge, abnormal breast growth, breast growth in males.
izcedek iz dojk, nenormalna rast dojk, rast tkiva dojk pri moških
Breast discharge, abnormal breast growth, breast growth in males.
Izcedek iz dojk, nenormalna rast dojk, rast tkiva dojk pri moških.
breast discomfort, breast engorgement, breast enlargement, vaginal discharge
neprijeten občutek v dojkah, nabreklost dojk, povečanje dojk, izcedek iz nožnice
breast discomfort, enlargement of the glands in your breasts, breast enlargement, vaginal discharge very low body temperature, chills, an increase in body temperature, feeling thirsty, symptoms of drug withdrawal, accumulation of pus caused by infection at injection site, deep skin infection, a cyst at the injection site, bruising at injection site.
bolečine v dojkah, povečanje žlez v dojkah, povečanje dojk, izcedek iz nožnice zelo nizka telesna temperatura, mrazenje, zvišanje telesne temperature, občutek žeje, simptomi odtegnitve zdravila, kopičenje gnoja zaradi okužbe na mestu injiciranja, globoka okužba kože, cista na mestu injiciranja, modrica na mestu injiciranja
Breast disorder female, breast induration, breast pain, cervix disorder, cervical dysplasia, cervical polyp, colpocele, endometrial hyperplasia** (based on investigator reporting), genital discharge, genital haemorrhage, hydrometra, metrorrhagia, postmenopausal haemorrhage, rectocele, uterine cervical erosion, uterine prolapse, vaginal haemorrhage, vaginal prolapse, vulvovaginal pruritus
bolezen dojke, induracija dojke, bolečina v dojki, bolezen materničnega vratu, cervikalna displazija, cervikalni polip, kolpokela, endometrijska hiperplazija** (na podlagi poročanja raziskovalcev), izcedek iz spolovil, genitalna krvavitev, hidrometra, metroragija, postmenopavzna krvavitev, rektokela, erozija materničnega vratu, prolaps maternice, krvavitev iz nožnice, prolaps nožnice, vulvovaginalni pruritus
breast disorders
bolezni dojk
Breast disorders
motnje dojk
breast disorders
Motnje reprodukcije in dojk
breast disorders
obolenja dojk
Breast disorders
premembe v dojkah
Breast enlargement
povečanje dojk,
Breast enlargement Galactorrhea in females Gynaecomastia/breast enlargement in males
Povečanje dojk Galaktoreja pri ženskah Ginekomastija/po večanje dojk pri moških
Breast enlargement Galactorrhea in females Gynaecomastia/breast enlargement in males
Povečanje dojk Galaktoreja pri ženskah Ginekomastija/poveča nje dojk pri moških
Breast enlargement has been observed with INCRELEX treatment.
Pri zdravljenju z zdravilom INCRELEX so poročali o povečanju dojk.
breast enlargement in males
povečanje prsi pri moških
breast enlargement in males
povečanje prsi pri moških;
breast enlargement in men
povečanje dojk pri moških
breast enlargement in men
povečanje prsi pri moškem
breast enlargement in men symptoms of restless legs syndrome (an irresistable urge to move a part of the body, usually the leg, accompanied by uncomfortable sensations)
povečanje dojk pri moških simptomi sindroma nemirnih nog (neustavljiva potreba po premiku dela telesa, običajno nog, ki jo spremljajo neprijetni občutki)
Breast enlargement**** Breast pain**** Galactorrhoea**** Erectile dysfunction**** Amenorrhoea**** Dysmenorrhoea****
povečanje dojk**** bolečina v dojkah**** galaktoreja**** erektilna disfunkcija**** amenoreja**** dismenoreja
Breast feeding
Brjóstagjöf
Breast feeding (see sections 4.6 and 5.3)
Dojenje (glejte poglavji 4.6 in 5.3).
Breast feeding in women receiving Latuda should be considered only if the potential benefit of treatment justifies the potential risk to the child.
Doječe matere se z zdravilom Latuda lahko zdravijo le, če možna korist zdravljenja odtehta možno tveganje za dojenega otroka.
Breast inflammation
vnetje dojk
breast inflammation*
vnetje dojke*,
Breast inflammation/mastitis
vnetje dojk/mastitis
Breast mass
Telesna masa
Breast mass
zatrdlina v dojki
Breast milk should be discarded within the first 24 hours after thrombolytic therapy.
V prvih 24 urah po trombolitičnem zdravljenju je treba materino mleko zavreči.
breast overdevelopment in men adrenal insufficiency
pretiran razvoj dojk pri moških; oslabljeno delovanje nadledvične žleze.
breast pain
boleče dojke,
Breast pain
bolečina v dojkah
Breast pain
bolečine v dojkah
breast pain
bolečine v prsih
breast pain, breast discomfort, enlargement of the glands in your breasts, breast enlargement, discharge from the breasts
bolečina v dojkah, nelagodje v dojkah, povečanje žlez v dojkah, povečanje dojk, izcedek iz dojk
Breast pain, breast tenderness, swollen breasts
bolečine v dojkah, občutljivost dojk, otekle dojke;
Breast pain, tenderness, enlargement, discharge; leucorrhoea
bolečine v dojkah, občutljivost dojk, povečanje dojk, izcedek iz dojk, levkoreja
Breast pain.
bolečina v dojkah
Breast pain.
Bolečina v dojkah.
Breast problems such as pain, enlargement or lumps in the breast
premembe v dojkah, kot je bolečina, povečane dojke ali zatrdline v dojkah
breast swelling in boys
otekanje prsi pri fantih
Breast tenderness
občutljivost dojk
Breast tenderness Hypertrophy breast
občutljivost dojk
Breast, cervical or liver cancer
rak dojke, materničnega vratu ali jeter
breast, ovarian, testicular), squamous cell
z dojkami, jajčniki in testisi), ploščatocelični
Breast- feeding must therefore be avoided.
Zato se je treba dojenju izogibati.
Breast-feeding
Dojenje.
Breast-feeding
Dojenje:
Breast-feeding
Dojenjne
Breast-feeding
Imunosupresivi
Breast-feeding
Nosečnost
Breast-feeding (see section 4.6).
Dojenje (glejte poglavje 4.6)
Breast-feeding is contraindicated while taking mitotane (see section 4.3) and after treatment discontinuation as long as mitotane plasma levels are detectable.
Med jemanjem mitotana (glejte poglavje 4.3) in po prekinitvi zdravljenja, dokler so plazemske koncentracije mitotana zaznavne, je dojenje kontraindicirano.
Breast-feeding is not recommended during treatment with Arzerra and for 12 months after the last time you were treated with Arzerra.
Dojenje ni priporočljivo med zdravljenjem z zdravilom Arzerra in še 12 mesecev potem, ko ste dobili zadnji odmerek tega zdravila.
Breast-feeding is not recommended during treatment with Leganto.
Dojenje med zdravljenjem z zdravilom Leganto ni priporočljivo.
Breast-feeding is not recommended during treatment with Neupro.
Dojenje med zdravljenjem z zdravilom Neupro ni priporočljivo.
Breast-feeding is not recommended during treatment with Tasigna.
Dojenje ni priporočeno v času jemanja zdravila Tasigna.
Breast-feeding is not recommended during treatment with Tracleer.
V času jemanja zdravila Tracleer se dojenje odsvetuje.
Breast-feeding mothers
Doječe matere
Breast-feeding mothers of newborn infants treated with caffeine citrate should not ingest caffeine- containing foods and beverages or medicinal products containing caffeine (see section 4.6), since caffeine is excreted into breast milk (see section 5.2).
Doječe matere novorojenčkov, ki jih zdravijo s kofeinijevim citratom, ne smejo uživati hrane in pijače, ki vsebuje kofein ali zdravil, ki vsebujejo kofein (glejte poglavje 4.6), saj se kofein izloča v materino mleko (glejte poglavje 5.2).
Breast-feeding mothers of newborn infants treated with caffeine citrate should not ingest caffeine- containing foods, beverages or medicinal products containing caffeine.
Doječe matere novorojenčkov, zdravljenih s kofeinijevim citratom, naj ne uživajo hrane, pijače ali zdravil, ki vsebujejo kofein.
Breast-feeding mothers should not breast- feed for 24 hours after treatment with this medicine.
Matere, ki dojijo, ne smejo dojiti vsaj 24 ur po uporabi tega zdravila.
Breast-feeding mothers should not take Kaletra unless specifically directed by the doctor.
Doječe matere ne smejo jemati zdravila Kaletra, razen če jim tega posebej ne naroči zdravnik.
Breast-feeding mothers should not take lopinavir/ritonavir unless specifically directed by the doctor.
Doječe matere ne smejo jemati lopinavirja/ritonavirja, razen če jim tega posebej ne naroči zdravnik.
Breast-feeding must be discontinued in women who are receiving therapy with Tyverb.
Med zdravljenjem z zdravilom Tyverb mora ženska prenehati z dojenjem.
Breast-feeding must be stopped on initiation of treatment with Voriconazole Hospira.
Ko se začne zdravljenje z zdravilom Vorikonazol Hspospira, mora ženska prenehati z dojenjem.
Breast-feeding should be avoided if you are on Wilzin therapy.
Če se zdravite z Wilzinom, se izogibajte dojenju.
Breast-feeding should be discontinued during treatment with Akynzeo and for 1 month after the last dose.
Med zdravljenjem z zdravilom Akynzeo in še 1 mesec po zadnjem odmerku je treba prenehati z dojenjem.
Breast-feeding should be discontinued during treatment with asfotase alfa.
Med zdravljenjem z asfotazo alfa je treba prenehati z dojenjem.
Breast-feeding should be discontinued during treatment with bosutinib.
Med zdravljenjem z bosutinibom je treba dojenje prekiniti.
Breast-feeding should be discontinued during treatment with pazopanib.
Med zdravljenjem s pazopanibom mora bolnica prenehati dojiti.
Breast-feeding should be discontinued during treatment with Pradaxa.
Med zdravljenjem z zdravilom Pradaxa mora ženska prenehati dojiti.
Breast-feeding should be discontinued during treatment with this medicine.
Med zdravljenjem s tem zdravilom je treba prenehati z dojenjem.
Breast-feeding should be discontinued for at least 4 days after NexoBrid application.
Po nanosu zdravila NexoBrid je treba za vsaj 4 dni prenehati z dojenjem.
Breast-feeding should be discontinued while receiving treatment with capecitabine.
Med zdravljenjem s kapecitabinom je treba dojenje prekiniti.
Breast-feeding should be interrupted for 12 hours after application of Ameluz.
Po uporabi zdravila Ameluz je treba za 12 ur prenehati z dojenjem.
Breast-feeding should be terminated prior to treatment.
Pred začetkom zdravljenja je treba prenehati dojiti.
Breast-feeding while taking INCRELEX is not recommended.
Med zdravljenjem z zdravilom INCRELEX dojenje ni priporočljivo.
Breast-feeding women (see section 4.6).
Doječe ženske (glejte poglavje 4.6).
Breast-feeding women may require adjustments in insulin dose and diet.
Pri nosečnicah so lahko potrebne prilagoditve odmerka insulina in prehrane.
Breast-feeding women must, therefore, not receive teriflunomide.
Zato doječe matere ne smejo prejemati teriflunomida.
Breast-feeding.
Dojenje;
Breast-feeding.
holestaza, dojenje.
Breast-feeding: it is unknown whether bexarotene is excreted in human milk.
Dojenje: ni znano, ali se beksaroten izloča v materino mleko.
Breast-Feeding: Women taking Axura should not breast-feed.
Dojenje: Ženske, ki jemljejo zdravilo Axura, ne smejo dojiti.
Breast-Feeding: Women taking Memantine Merz should not breast-feed.
Dojenje: Ženske, ki jemljejo zdravilo Memantine Merz, ne smejo dojiti.
Breastfed infants, if the mother is treated with medicines contraindicated with propranolol
Dojeni otroci, če je bila mati zdravljena z zdravili, ki so kontraindicirana s propranololom
Breastfeeding
Dojenje;
Breastfeeding
Kontraindikacije
Breastfeeding is not recommended during treatment with sodium oxybate.
Med zdravljenjem z natrijevim oksibatom dojenje ni priporočljivo.
Breastfeeding is not recommended when you take Zalviso.
Med jemanjem zdravila Zalvisa ne smete dojiti.
Breastfeeding is not recommended while taking DUTREBIS.
Ni priporočljivo, da ženska med jemanjem zdravila DUTREBIS doji.
Breastfeeding is not recommended while taking ISENTRESS.
Med zdravljenjem z zdravilom ISENTRESS dojenja ne priporočamo.
Breastfeeding mothers: see section 4.4 and section 4.5.
Doječe matere: glejte poglavje 4.4 in poglavje 4.5.
Breastfeeding should be discontinued during treatment with ofatumumab and for 12 months following treatment.
Dojenje je treba prekiniti med zdravljenjem z ofatumumabom in v obdobju 12 mesecev po zdravljenju.
Breastfeeding women must not take this medicine.
Ženske, ki dojijo, ne smejo jemati tega zdravila.
Breasts
0,005
Breasts
Dojke
Breasts
dojki
Breasts
prsi
Breasts3
dojke3
Breath odour
zadah
Breath sample container
Epruvete za vzorce izdihanega zraka
BREATH SAMPLE CONTAINERS: GLASS OR PLASTIC
EPRUVETE ZA VZORCE IZDIHANEGA ZRAKA: STEKLENE ALI PLASTIČNE
Breath samples collected during the test must remain in the original containers before analysis by IRMS.
Vzorci izdihanega zraka, ki se zbirajo med testom, morajo pred analizo z IRMS ostati v originalnih vsebnikih.
Breath sounds abnormal
nenormalen zvok dihanja
Breathe in rapidly but steadily and as deeply as you can.
Da bi zdravilo lahko vdihnili globoko v dihalne poti:
Breathe in rapidly but steadily and as deeply as you can.
Hitro in enakomerno vdihnite, kolikor globoko morete.
Breathe in rapidly but steadily, as deeply as you can.
Da bi zdravilo lahko vdihnili globoko v dihalne poti:
Breathe in rapidly but steadily, as deeply as you can.
Hitro in enakomerno vdihnite, kolikor globoko morete.
Breathe normally (inhale and exhale) through the mouthpiece.
Normalno dihajte (vdihavajte in izdihavajte) skozi ustnik.
Breathe out
Izdih
Breathe out slowly and gently.
Počasi in previdno izdihnite.
Breathe out slowly and gently.
Počasi in previdno naj izdihne.
Breathe out, and then breathe normally again.
Izdihnite in spet normalno dihajte.
Breathe out:
Vdihnite zdravilo:
breathing difficulties
težave pri dihanju
breathing difficulties
težave z dihanjem
Breathing difficulties
težave z dihanjem zvišanje ravni jetrnih encimov
Breathing difficulties
težave z dihanjem,
breathing difficulties (dyspnoea)
težave z dihanjem (dispneja)
breathing difficulties (dyspnoea)
težave z dihanjem (dispneja),
Breathing difficulties (slow or shallow breathing)
oteženo dihanje (počasno ali plitvo dihanje),
breathing difficulties and/or heart/ pulse-rate/ blood pressure disturbances which may lead to consciousness disorders respiratory reactions, and /or cardiovascular manifestations which may lead to shock).
kožne reakcije, težave pri dihanju in/ali motnje delovanja srca, srčnega utripa ali krvnega tlaka, ki lahko pripeljejo do motenj zavesti (kožnih ali dihalnih reakcij in/ali srčno-žilnih znakov, ki lahko pripeljejo do šoka).
Breathing difficulties or wheezing that gets worse straight after taking Aerivio Spiromax.
Poslabšanje težav z dihanjem ali piskajočega dihanja takoj po uporabi zdravila Aerivio Spiromax.
Breathing difficulties or wheezing that gets worse straight after taking Aerivio Spiromax.
Poslabšanje težav z dihanjem ali piskajočega dihanja takoj po uporabi zdravila Airexar Spiromax.
breathing difficulties sometimes associated with cough
težave pri dihanju, ki so včasih povezane s kašljem,
breathing difficulties, cough, chest pain
oteženo dihanje, kašelj, bolečine v prsnem košu,
breathing difficulties, hoarseness, difficulty in speaking skin redness, nettle rash (urticaria) or itching.
težave pri dihanju, hripavost, težave pri govoru rdečica kože, koprivnica (urtikarija) ali srbenje
breathing disorders
motnje dihanja;
breathing disorders, shortness of breath, inflammation of the lungs.
dihalne motnje, kratka sapa, vnetje pljuč;
Breathing problems
Težave z dihanjem
breathing problems (including shortness of breath),
težave z dihanjem (vključno s kratko sapo),